Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) reported Tuesday financial results for the fourth quarter and full year ended December 31, 2021.
“In 2022, we look to build on last year’s progress as we continue to enroll patients in our confirmatory pivotal Phase 3 trial in Fragile X syndrome, initiate a Phase 3 program in autism spectrum disorder and report topline results in our Phase 2 trial in 22q11.2 deletion syndrome,” Armando Anido, chairman and chief executive officer of Zynerba stated. “We are committed to achieving our goal of bringing the first pharmaceutical product indicated for the treatment of behavioral symptoms of Fragile X syndrome to market, as well as advancing Zygel in other rare and near rare neuropsychiatric indications.”
